HIV/AIDS Research

Kaletra combination therapy shown to maintain undetectable viral load in HIV patients

Published in Vaccine Weekly, December 21st, 2005

The longest clinical study of any HIV treatment - 7 years (360 weeks) - of Kaletra (lopinavir/ritonavir)-based therapy study results demonstrated patients taking Kaletra in combination with other antiretroviral agents maintained an undetectable viral load of less than 50 copies per milliliter, as measured by HIV RNA.

This data, presented at the 9th European AIDS Conference (EACS), demonstrated that most patients taking a Kaletra-based regimen as initial therapy for HIV infection showed sustained antiviral response. Of the 19 patients who met criteria for resistance testing and had resistance testing results available through week 360, none demonstrated primary protease...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-12-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry